20305-1-AP

antibody from Proteintech Group

Targeting: CD47 IAP, MER6, OA3

Provider product page for 20305-1-AP

Western blot

ELISA

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [19]
Comments [0]
Validations
Western blot [1]

Submit

Product number: 20305-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#20305-1-AP, RRID:AB_10732838
Product name: CD47 antibody
Antibody type: Polyclonal
Description: CD47 antibody (Cat. #20305-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, ELISA.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

CD47 protein structure - 20305-1-AP shown in red.

Submitted references Efficient Delivery of Lomitapide using Hybrid Membrane-Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy.

Song M, Tian J, Wang L, Dong S, Fu K, Chen S, Liu C
Advanced materials (Deerfield Beach, Fla.) 2024 Jun;36(24):e2311760

Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.

Chong L, Jiang YW, Wang D, Chang P, Xu K, Li J
Journal of nanobiotechnology 2023 Oct 31;21(1):401

Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.

Zhang L, Zhao X, Niu Y, Ma X, Yuan W, Ma J
Journal of extracellular vesicles 2023 Nov;12(11):e12379

Immunostimulation with chemotherapy of a ruthenium-arene complex via blockading CD47 signal in chronic myelogenous leukemia cells.

Hu G, Lv M, Guo B, Huang Y, Su Z, Qian Y, Xue X, Liu HK
Journal of inorganic biochemistry 2023 Jun;243:112195

RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation.

Zhang L, Yu J, Zheng M, Zhen H, Xie Q, Zhang C, Zhou Z, Jin G
Communications biology 2023 Feb 23;6(1):211

α5-nAChR/STAT3/CD47 axis contributed to nicotine-related lung adenocarcinoma progression and immune escape.

Kang G, Jiao Y, Pan P, Fan H, Li Q, Li X, Li J, Wang Y, Jia Y, Wang J, Sun H, Ma X
Carcinogenesis 2023 Dec 15;44(10-11):773-784

PPARγ agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape.

Xu L, Che S, Chen H, Liu Q, Shi J, Jin J, Hou Y
Journal of cellular biochemistry 2023 Aug;124(8):1145-1154

MiR-133a/CD47 axis is a novel prognostic biomarker to promote triple negative breast cancer progression.

Yan H, Huang W, Chen C, Zhang X, Zhu K, Yuan J
Pathology, research and practice 2023 Apr;244:154400

CD47 interactions with exportin-1 limit the targeting of m(7)G-modified RNAs to extracellular vesicles.

Kaur S, Saldana AC, Elkahloun AG, Petersen JD, Arakelyan A, Singh SP, Jenkins LM, Kuo B, Reginauld B, Jordan DG, Tran AD, Wu W, Zimmerberg J, Margolis L, Roberts DD
Journal of cell communication and signaling 2022 Sep;16(3):397-419

Engineered biomimetic nanoreactor for synergistic photodynamic-chemotherapy against hypoxic tumor.

Guo H, Wang L, Wu W, Guo M, Yang L, Zhang Z, Cao L, Pu F, Huang X, Shao Z
Journal of controlled release : official journal of the Controlled Release Society 2022 Nov;351:151-163

Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy.

Guo H, Zhang W, Wang L, Shao Z, Huang X
Biomaterials 2022 Nov;290:121821

Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting.

Wan S, Wu Y, Fan Q, Yang G, Hu H, Tima S, Chiampanichayakul S, Anuchapreeda S, Wu J
Pharmaceutics 2022 Nov 26;14(12)

Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer.

Yang XY, Zhang JG, Zhou QM, Yu JN, Lu YF, Wang XJ, Zhou JP, Ding XF, Du YZ, Yu RS
Journal of nanobiotechnology 2022 Dec 10;20(1):524

Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis.

Zhao Q, Cai Q, Yu S, Ji J, Zhu Z, Yan C, Zhang J
Frontiers in cell and developmental biology 2021;9:745120

Bioengineering CXCR4-overexpressing cell membrane functionalized ROS-responsive nanotherapeutics for targeting cerebral ischemia-reperfusion injury.

Luo L, Zang G, Liu B, Qin X, Zhang Y, Chen Y, Zhang H, Wu W, Wang G
Theranostics 2021;11(16):8043-8056

Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.

Fu F, Zhang Y, Gao Z, Zhao Y, Wen Z, Han H, Li Y, Hu H, Chen H
Journal of cancer research and clinical oncology 2021 Mar;147(3):739-747

4T1 cell membrane fragment reunited PAMAM polymer units disguised as tumor cell clusters for tumor homotypic targeting and anti-metastasis treatment.

Pei X, Pan X, Xu X, Xu X, Huang H, Wu Z, Qi X
Biomaterials science 2021 Feb 23;9(4):1325-1333

Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.

Kaur S, Schwartz AL, Jordan DG, Soto-Pantoja DR, Kuo B, Elkahloun AG, Mathews Griner L, Thomas CJ, Ferrer M, Thomas A, Tang SW, Rajapakse VN, Pommier Y, Roberts DD
Frontiers in oncology 2019;9:994

Aptamer-Based Erythrocyte-Derived Mimic Vesicles Loaded with siRNA and Doxorubicin for the Targeted Treatment of Multidrug-Resistant Tumors.

Wang T, Luo Y, Lv H, Wang J, Zhang Y, Pei R
ACS applied materials & interfaces 2019 Dec 11;11(49):45455-45466

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: The CD47 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human CD47. This antibody recognizes human antigen. The CD47 antibody has been validated for the following applications: ELISA, WB analysis.
Appendix: 20305-1-AP.pdf

: Show more